Islatravir/​Lenacapavir with Bictegravir/​Emtricitabine/​Tenofovir Alafenamide (ISLEND-1)

November 2, 2026: Merck (NYSE: MRK) said it will present HIV treatment and prevention data at HIV Drug Therapy Glasgow 2026 (Nov. 8–11, 2026).

IDVYNSO (doravirine/islatravir): Merck will present Phase 3 analyses including Week 48 resistance and weight data from Trial 53 in previously untreated adults with HIV-1 versus BIC/FTC/TAF, plus Week 96 patient-reported outcomes in virologically suppressed adults. Merck also said the FDA accepted two supplemental NDAs for IDVYNSO—one based on Phase 3 Trial 053 in treatment-naive adults and one based on Trials 051/052 to add 96-week data in virologically suppressed adults—with a PDUFA date of April 22, 2027.

Islatravir/lenacapavir (ISL/LEN): HIV Glasgow presentations will include Week 48 subgroup safety/efficacy analyses from the Phase 3 ISLEND-1 and ISLEND-2 trials in virologically suppressed adults switching to once-weekly oral therapy; ISLEND-2 will also include Week 48 patient-reported outcomes and a qualitative substudy on participant/provider experience.

Islatravir/ulonivirine: Merck will present Week 24 Phase 2b PK-modeling data supporting once-weekly ulonivirine 200 mg plus islatravir 2 mg, plus Phase 1 ulonivirine ADME data.

Alimatravir (MK-8527): demographic data from the adult cohorts of the ongoing Phase 3 EXPrESSIVE-10 and EXPrESSIVE-11 once-monthly oral PrEP trials will be presented; adult enrollment in both studies is complete.